• Personalized Medicine Coalition Applauds Data Presentations at IASLC/ESMO ELCC

    May 10, 2010 The Personalized Medicine Coalition (PMC) applauds the substantial number of new studies focusing on targeted approaches to the treatment of lung cancer presented at the second joint European Lung Cancer Conference of the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) in Geneva. “The number of studies ... Read more
  • New Blood Test May Help in the Fight Against Lung Cancer (Queen’s University)

    May 6, 2010 A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively to the drug. Currently, patients with non-small cell lung cancer receive erlotinib after chemotherapy and other drugs have failed. But erlotinib will only shrink the tumour about 10 per cent ... Read more
  • Biodesix: A New Way to Inform Cancer Treatment Selection (Rocky Radar)

    October 29, 2009 “One data point doesn’t tell you very much in most cases,” comments David Brunel, CEO of Biodesix, a medical diagnostics company based in Broomfield, Colorado. This principle guides Biodesix’s approach to developing diagnostics which aim to identify a patient’s expected response to a particular therapeutic. This story is no longer available from Rocky Radar. For Customer Support, call: ... Read more